ETF收评：创新药ETF沪港深领涨4.10%，科创综指ETF嘉实领跌14.01%

Group 1 - The ETF market showed mixed performance, with the innovative drug ETFs leading gains, particularly the Shanghai-Hong Kong-Shenzhen innovative drug ETF (159622) which rose by 4.10% [1] - The Hong Kong innovative drug 50 ETF (513780) increased by 4.04%, while the Hong Kong innovative drug ETF (513120) saw a rise of 4.01% [1] - Conversely, the STAR Market comprehensive index ETF by Harvest (589300) experienced a significant decline of 14.01%, indicating a notable downturn in that sector [1] Group 2 - The energy and chemical ETF (159981) fell by 4.12%, and the coal ETF (515220) decreased by 2.87%, reflecting challenges in those industries [1] - There is a suggestion to utilize T+0 trading through ETFs to invest in Hong Kong innovative drug stocks, indicating a strategic approach to capitalize on the sector's performance [1]